Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003)
Makoto Yamasaki(The University of Osaka), Yuichiro� Doki(Osaka Gakuin University), Hiroshi Miyata(Osaka University), Taroh Satoh(Osaka University Hospital), Osamu Shiraishi(Kindai University), Kazumasa Fujitani(Osaka Prefectural Medical Center), Shigeyuki Tamura(Kansai Rosai Hospital), Masaki Mori(Tokai University), Tomoki Makino(The University of Osaka), Yutaka Kimura(Kansai Medical University), Takushi Yasuda(Osaka International Cancer Institute), Motohiro Hirao(Osaka National Hospital), Masahiko Yano(Nagoya Sangyo University), Kazuma Kobayashi(Kinki Central Hospital), Masaaki Motoori(Osaka International Cancer Institute)
Cited by 128
Related Papers
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670
Large-scale genome-wide association study in a Japanese population identifies novel susceptibility loci across different diseases
|Nature Genetics|2020|599
A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected Lung Cancers
|Journal of Thoracic Oncology|2008|424
Genome-wide Expression Analysis of Mouse Liver Reveals CLOCK-regulated Circadian Output Genes
|Journal of Biological Chemistry|2003|347